Corporate

Berlin Pharmaceutical and Acino Pharma Sign Partnership in Thailand

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s products in Thailand

Published

9 years ago

September 5, 2011

Akanksha Singh

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG (SIX: ACIN) signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s current and future products in Thailand.

“The new products will complement our current line of therapies as well as significantly expand our presence into new areas,” said Amal Naj, Chief Executive Officer of Berlin. “We are very excited about this association with Acino and the high quality products we will bring to our patients at affordable prices,” he said.

Peter Burema, CEO of Acino Group

Peter Burema, CEO of Acino Group, said,

“We are very pleased to partner with one of the leading pharmaceutical companies in Thailand to introduce our products in the market. We see great opportunities for our products there and rest of Asia and other emerging markets.”

Acino, based in Basle, Switzerland, specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe

Mr. Naj said the vast majority of the Acino products Berlin will introduce in Thailand are for the treatment of urological disorders, cancer and pain. The company’s current products are prescribed mainly for the treatment of cardiovascular and metabolic diseases and gastro-intestinal disorders.

Mr. Naj said a number of Acino products are innovative, and they will help strengthen Berlin’s market presence in the highly competitive market.

Berlin currently manufactures most of its products in GMP-approved (Good Manufacturing Practice) and ISO-certified facilities, and imports active pharmaceutical ingredients (API) as well as finished products from Canada, France, and India.

Berlin is one of the top 10 pharmaceutical companies in Thailand and is a market leader in many of the products it markets. The company employs 550 people.

The Acino Group is headquartered in Basle, and currently employs approximately 380 staff. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN).

Please note that under Thai FDA regulation, we cannot discuss individual products.

CONTACT

Pajasalmi, Ruangkittikul & Associates Ltd.

Khun Panarasee Thaiwatcharamas

Khun Komson Kaemthong

+662 651 8989 Ext. 222 and 441

Berlin Pharmaceutical Industry

Amal Naj, CEO

+662 652 9590

[email protected]

Acino Pharma AG

Peter Burema, CEO

+41 61 338 60 00

[email protected]

www.acino-pharma.com

SOURCE Berlin Pharmaceutical Industry

Corporate

How will recruitment change following COVID‑19?

Remote working, distributed workforces and a greater demand for flexibility are all factors affecting how businesses and candidates think about work opportunities

Published

13 hours ago

January 27, 2021

Daniel Lorenzzo

A laptop with hands holding a phone, with a cat lying by the side

At the start of the 2020 pandemic, recruitment wasn’t high on the list of priorities for many businesses. In fact, it was just the opposite – across the globe there were hiring freezes and the large-scale furloughing of staff.

(more…)

Corporate

Covid-19 puts flexible space markets under strain

In the wake of operator defaults, landlords will be forced to re-evaluate the role of flexible space in their portfolios.

Published

2 days ago

January 26, 2021

Daniel Lorenzzo

The global Covid-19 outbreak has had serious negative effects on commercial real estate, including flexible space. Of late, many operators have experienced the flexible nature of the business working against them, as many occupiers have opted to surrender desks and implement work-from-home plans.

(more…)

Business

Thailand’s automotive sector expected to produce 1.4m cars this year

This increase in output is a result of the recovery of domestic and export markets, with the annual output for 2021 expected to be around 1.4 million.

Published

3 days ago

January 25, 2021

National News Bureau of Thailand

Thailand Automotive Institute (TAI) anticipates the overall output from Thailand’s automotive sector this year to be around 1.4 million cars. They are, however, still cautious over automobile exports until at least March this year, due to the resurgence of COVID-19 cases around the world.

(more…)